[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2015/92420,2015,A1
[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2015/92420,2015,A1
[2]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2021/225955,2021,A1
[3]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2021/225955,2021,A1
[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2015/92420,2015,A1Locationinpatent:Page/Pagecolumn147
[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2015/92420,2015,A1
[1]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2015/92420,2015,A1
[2]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2021/225955,2021,A1
[3]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2021/225955,2021,A1
[4]CurrentPatentAssignee:OTSUKAHOLDINGSCOLTD-WO2021/225955,2021,A1
Title: Tomoko Smyth, et al. Abstract 1287: The dual IAP antagonist, ASTX660, increases the anti-tumor activity of NSC 125973 in preclinical models of triple-negative breast cancer in vivo. Cancer Res 2016;76(14 Suppl).